细胞膜上GABBR2表达量的增加导致Ca2+向内流量的增加,与早期阿尔茨海默病的认知障碍有关
1Department of Neurology, The Affiliated People's Hospital of Ningbo University, No.251 East Baizhang Road, Ningbo, 315040, Zhejiang, China.
Biochemical genetics
|December 26, 2024
概括
过度表达GABBR2与早期阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 有关. 这种分子变化会触发细胞事件,如不平衡,氧化应激和线粒体功能障碍,导致疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 构成了全球重大健康挑战.
- 了解早期AD和MCI的分子机制对于开发有效的干预措施至关重要.
研究的目的:
- 研究早期阿尔茨海默病 (AD) 进展和轻度认知障碍 (MCI) 中关键的分子病理机制.
- 分析患有MCI和正常对照个体的大脑同质体中的基因表达特征.
主要方法:
- 分析了GSE12685 (8名正常志愿者,6名MCI患者) 的表达特征分析数据.
- 在人类神经母细胞瘤细胞系 (SH-SY5Y,BE(2) -M17) 中,GABBR2通过等离子体转染过度表达.
主要成果:
- 与正常大脑相比,GABBR2在MCI患者的大脑组织中显著过度表达.
- 细胞系中GABBR2的过度表达导致了细胞内Ca2+度的增加,反应性氧物种 (ROS) 的产生,线粒体透性过渡孔口的开放,以及亡.
- GABBR2过度表达与细胞事件有关,包括细胞内Ca2+失衡,氧化应激和线粒体功能障碍.
结论:
- 在阿尔茨海默氏症和轻度认知障碍的早期进展中,GABBR2发挥着重要作用.
- 分子机制涉及通过GABBR2过度表达诱导细胞应激途径和亡.
相关概念视频
01:26Alzheimer's Disease: Overview
313
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.0K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.0K
01:22Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125